A mutant of the haloalkane dehalogenase DhaA (DhaA31) from R. rhodochrous NCIMB 13064 and its complex with 1,2,3-trichloropropane were crystallized and the crystals diffracted to high resolution.
Keywords: haloalkane dehalogenases, DhaA, Rhodococcus rhodochrous
Abstract
Haloalkane dehalogenases hydrolyze carbon–halogen bonds in a wide range of halogenated aliphatic compounds. The potential use of haloalkane dehalogenases in bioremediation applications has stimulated intensive investigation of these enzymes and their engineering. The mutant DhaA31 was constructed to degrade the anthropogenic compound 1,2,3-trichloropropane (TCP) using a new strategy. This strategy enhances activity towards TCP by decreasing the accessibility of the active site to water molecules, thereby promoting formation of the activated complex. The structure of DhaA31 will help in understanding the structure–function relationships involved in the improved dehalogenation of TCP. The mutant protein DhaA31 was crystallized by the sitting-drop vapour-diffusion technique and crystals of DhaA31 in complex with TCP were obtained using soaking experiments. Both crystals belonged to the triclinic space group P1. Diffraction data were collected to high resolution: to 1.31 Å for DhaA31 and to 1.26 Å for DhaA31 complexed with TCP.
1. Introduction
The haloalkane dehalogenase DhaA was isolated from the Gram-positive bacterium Rhodococcus rhodochrous NCIMB 13064 (Kulakova et al., 1997 ▶). The enzyme catalyzes the hydrolytic dehalogenation of various halogenated aliphatic hydrocarbons. The structures of several DhaA mutant variants have been published (Newman et al., 1999 ▶; Klvana et al., 2009 ▶; Stsiapanava et al., 2010 ▶). The main α/β-hydrolase domain is conserved in the members of the α/β-hydrolase superfamily and serves as a scaffold for the catalytic residues. The second helical cap domain is structurally more variable and is known to influence the substrate specificity of these enzymes (Chovancová et al., 2007 ▶). The active-site cavity is located between two protein domains and is connected to the protein surface by two major access tunnels: the main tunnel and the slot tunnel used by the ligands for exchange between the active site and the surrounding solvent. A catalytic pentad of DhaA which performs hydrolysis has been identified. It includes a nucleophile (Asp106), a base (His272), a catalytic acid (Glu130) and two halide-stabilizing residues (Asn41 and Trp107). The dehalogenation reaction proceeds in the active site via nucleophilic attack of a nucleophile on a C atom carrying a halogen on the substrates. This leads to cleavage of the carbon–halogen bond, displacement of the halide and the formation of a covalent alkyl-enzyme intermediate. The alkyl-enzyme intermediate is subsequently hydrolyzed by a water molecule activated by a catalytic base (Pavlova et al., 2009 ▶).
Some haloalkane dehalogenases are involved in the biodegradation of important environmental pollutants. The enzyme DhaA is of particular interest because it enables a very slow conversion of the toxic artificial compound and suspected human carcinogen 1,2,3-trichloropropane (TCP) to 2,3-dichloropropane-1-ol under laboratory conditions (Schindler et al., 1999 ▶; Bosma et al., 1999 ▶). To increase the efficiency of this reaction, focused directed evolution was used to construct the mutant DhaA31, which has up to 32-fold higher catalytic activity and 26-fold higher catalytic efficiency than the parent wild-type enzyme (Pavlova et al., 2009 ▶). The mutant DhaA31 has a k cat value of 1.26 s−1 and a K m value of 1.2 mM, while the wild type has a k cat value of 0.04 s−1 and a K m value of 1.0 mM. The positions for mutagenesis were selected by computer modelling and were randomized experimentally. DhaA31 has large aromatic residues at two of the three randomized positions and at two positions modified by site-directed mutagenesis. These changes enhance activity towards TCP by decreasing the accessibility of the active site to water molecules, thus promoting the formation of an activated complex. Kinetic analyses confirmed that the mutations improved carbon–halogen bond cleavage and shifted the rate-limiting step to the release of products (Pavlova et al., 2009 ▶). Comparison of the wild-type DhaA and the mutant DhaA31 structures both in the free form and in complex with TCP could provide valuable structural information on the molecular basis of the enhanced catalysis.
2. Materials and methods
2.1. Construction of the mutant, protein expression and purification
The recombinant gene dhaA31 carrying I135F, C176Y, V245F, L246I and Y273F mutations was obtained by focused directed evolution. The methodology has been described previously by Pavlova et al. (2009 ▶). The dhaA31 gene was carried by a pAQN vector downstream of the tac promotor (P tac), which was under the control of lacI q. Escherichia coli BL21 cells with the plasmid were cultured in 4 l Luria–Bertani medium at 310 K. The induction of enzyme expression at 303 K was initiated by the addition of isopropyl β-d-1-thiogalactopyranoside to a final concentration of 0.5 mM. The cells were harvested and disrupted by sonication using a Soniprep 150 (Sanyo Gallenkamp PLC, Loughborough, England). The supernatant was used after centrifugation at 21 000g for 1 h. The enzyme was purified by immobilized metal-affinity chromatography as described previously (Pavlova et al., 2009 ▶). The enzyme was bound to the resin in equilibration buffer (20 mM potassium phosphate buffer pH 7.5, 0.5 M sodium chloride and 10 mM imidazole). Unbound and nonspecifically bound proteins were washed out with buffer containing 37.5 mM imidazole. The target enzyme was eluted using buffer containing 300 mM imidazole. The active fractions were pooled and dialyzed overnight against 100 mM Tris–HCl buffer pH 7.5 without additives. The DhaA31 enzyme was stored in the same buffer. The entire purification process and storage took place at 277 K. The active fractions were pooled and dialyzed overnight against 100 mM Tris–HCl buffer pH 7.5 without additives. Protein concentrations were determined by the Bradford method (Bradford, 1976 ▶). SDS–PAGE was run on 15% polyacrylamide gels to check the purity of the protein.
2.2. Crystallization
Freshly isolated and purified DhaA31 enzyme in 100 mM Tris–HCl buffer pH 7.5 was used in crystallization experiments. Initial crystallization experiments were carried out by the sitting-drop vapour-diffusion method (Ducruix & Giegé, 1999 ▶) using CombiClover crystallization plates (EBS plates; Emerald BioSystems, Bainbridge Island, USA) at room temperature and subsequently at the lower temperature of 277 K. Protein microcrystals were obtained using a couple of precipitants from the commercial crystallization kit Crystal Screen (Hampton Research, Aliso Viejo, California, USA) and PEG-based conditions from the JBScreen Classic kit (Jena Bioscience GmbH, Jena, Germany). Three-dimensional crystals of the mutant protein DhaA31 were obtained at 277 K during a four-month optimization procedure. The droplets, which consisted of a 2–4 µl total volume with precipitant:protein ratios of 1:1 (drop volume 2 µl), 1:2 (3 µl) and 1:3 (4 µl), were equilibrated over 800 µl reservoir solution. DhaA31 monocrystals were grown in 2 µl droplets consisting of equal volumes of protein solution at a concentration of 7 mg ml−1 in 50 mM Tris–HCl buffer pH 7.5 and reservoir solution consisting of 29%(w/v) PEG 4000 and 100 mM MES sodium salt pH 6.4.
2.3. Data collection and processing
Diffraction data for DhaA31 and for DhaA31 complexed with TCP were collected on beamline X12 at EMBL Hamburg Outstation (Germany) at a fixed wavelength of 1.033 Å using a MAR CCD 225 mm detector. Prior to data collection, several crystals of DhaA31 were soaked with TCP (Fig. 1 ▶ b). In this soaking experiment, 50 µl TCP was added to 800 µl reservoir solution and left for 6 h at room temperature. Crystals were mounted in nylon loops (Hampton Research, Aliso Viejo, USA; Teng, 1990 ▶) directly from the test drop and were flash-frozen in a stream of nitrogen gas at 100 K without additional cryoprotection. The diffraction data for DhaA31 were collected in two steps. 120 low-resolution images were recorded with an oscillation angle of 3° and a crystal-to-detector distance of 300 mm. A high-resolution set of 360 images (50–1.31 Å) was collected with an oscillation angle of 1° and a crystal-to-detector distance of 100 mm. Similarly, diffraction data for DhaA31 in complex with TCP were collected in two steps. A set of 400 high-resolution images (50–1.26 Å) was recorded with a 0.5° oscillation angle and a crystal-to-detector distance of 100 mm and this was followed by the collection of 130 low-resolution image frames with a 1.5° oscillation angle and a crystal-to-detector distance of 300 mm. Data for both protein crystals were integrated and scaled using the HKL-2000 program package (Otwinowski & Minor, 1997 ▶).
Figure 1.
Crystals of the mutant haloalkane dehalogenase DhaA from R. rhodochrous NCIMB 13064: (a) DhaA31 and (b) DhaA31 complexed with TCP.
2.4. Preliminary structure solution
The structures of DhaA31 and of its complex with TCP were solved by the molecular-replacement method in MOLREP (Vagin & Teplyakov, 2010 ▶) using the structure of haloalkane dehalogenase DhaA from R. rhodochrous (PDB code 3fbw; Stsiapanava et al., 2010 ▶) as the search model. Rigid-body refinement was performed using the REFMAC5 program from the CCP4 program suite (Murshudov et al., 1997 ▶). R and R free were 0.234 and 0.257, respectively, for DhaA31 and 0.251 and 0.279, respectively, for DhaA31 complexed with TCP.
3. Results and discussion
The initial crystallization conditions for mutant haloalkane dehalogenase DhaA31 were identified using solution C3 of Crystal Screen (Hampton Research, Aliso Viejo, USA), which consisted of 0.1 M Na HEPES pH 7.5, 2%(v/v) PEG 400, 2.0 M ammonium sulfate, and solution D4 of the JBScreen Classic kit (Jena Bioscience GmbH, Jena, Germany), composed of 30%(w/v) PEG 4000, 100 mM sodium acetate pH 4.6, 200 mM ammonium sulfate. Using these conditions, DhaA31 protein microcrystals were grown in one week. During the optimization procedure, the initial crystallization conditions were slightly modified and resulted in the use of a final precipitant solution consisting of 29%(w/v) PEG 4000 and 100 mM MES sodium salt pH 6.4. Three-dimensional crystals of DhaA31 were grown at 277 K and reached final dimensions of 0.28 × 0.19 × 0.13 mm (Fig. 1 ▶ a) in three weeks.
Three-week-old single crystals of DhaA31 were used for soaking experiments followed by diffraction data collection at a synchrotron-radiation source. Single crystals of DhaA31 and of DhaA31 complexed with TCP were used for X-ray diffraction measurements. Data sets for DhaA31 and DhaA31 complexed with TCP were collected to maximum resolutions of 1.31 Å (Fig. 2 ▶ a) and 1.26 Å (Fig. 2 ▶ b), respectively. The crystals belonged to the triclinic space group P1, with unit-cell parameters a = 42.55, b = 44.37, c = 46.41 Å, α = 115.3, β = 98.5, γ = 109.5° for DhaA31 and a = 42.49, b = 44.39, c = 46.53 Å, α = 115.3, β = 97.7, γ = 109.5° for DhaA31 complexed with TCP. The asymmetric units of the crystals of DhaA31 and DhaA31 complexed with TCP contained one monomer, with solvent contents of 40.0 and 40.6%, respectively. The calculated Matthews coefficient (V M; Matthews, 1968 ▶) for one monomer of DhaA31 in the asymmetric unit was 2.05 Å3 Da−1 and that for DhaA31 in complex with TCP was 2.07 Å3 Da−1. Data-collection statistics for DhaA31 and its complex with TCP are presented in Table 1 ▶.
Figure 2.
Diffraction images of crystals of the mutant haloalkane dehalogenase DhaA from R. rhodochrous NCIMB 13064: (a) DhaA31, (b) DhaA31 complexed with TCP. The crystals diffracted to resolutions of 1.31 and 1.26 Å for DhaA31 and DhaA31 complexed with TCP, respectively.
Table 1. Data-collection statistics for crystals of DhaA31 and DhaA31 complexed with TCP.
Values in parentheses are for the highest resolution shell.
| DhaA31 | DhaA31–TCP | |
|---|---|---|
| Beamline | DESY X12 | DESY X12 |
| Detector | MAR CCD 225 mm | MAR CCD 225 mm |
| Wavelength (Å) | 1.033 | 1.033 |
| Resolution range (Å) | 50–1.31 (1.35–1.31) | 50–1.26 (1.27–1.26) |
| Space group | P1 | P1 |
| Unit-cell parameters (Å, °) | a = 42.55, b = 44.37, c = 46.41, α = 115.3, β = 98.5, γ = 109.5 | a = 42.49, b = 44.39, c = 46.53, α = 115.3, β = 97.7, γ = 109.5 |
| Measured reflections | 580117 | 537263 |
| Unique reflections | 297181 | 162936 |
| Multiplicity | 4.3 | 2.4 |
| Completeness (%) | 94.6 (90.3) | 92.4 (82.7) |
| Rmerge† (%) | 4.4 (8.1) | 3.3 (6.1) |
| 〈I/σ(I)〉 | 35.6 (18.3) | 41.1(17.6) |
R
merge =
, where Ii(hkl) is the intensity of the ith measurement of reflection hkl and 〈I(hkl)〉 is the average intensity of the reflection.
The structures are currently being refined and their interpretation will follow.
Acknowledgments
This work was supported by the Ministry of Education of the Czech Republic (LC06010, MSM6007665808, MSM0021622412 and CZ.1.05/2.1.00/01.0001) and by the Academy of Sciences of the Czech Republic (AV0Z60870520 and IAA401630901). We thank Paul Tucker for assistance with data collection and the EMBL for access to the X12 beamline at the DORIS storage ring of DESY in Hamburg. The research work of ML was supported by the University of South Bohemia, grant GAJU 170/2010/P.
References
- Bosma, T., Kruizinga, E., De Bruin, E. J., Poelarends, G. J. & Janssen, D. B. (1999). Appl. Environ. Microbiol. 65, 4575–4581. [DOI] [PMC free article] [PubMed]
- Bradford, M. M. (1976). Anal. Biochem. 72, 248–254. [DOI] [PubMed]
- Chovancová, E., Kosinski, J., Bujnicki, J. M. & Damborský, J. (2007). Proteins, 67, 305–316. [DOI] [PubMed]
- Ducruix, A. & Giegé, R. (1999). Protein Crystallography: A Practical Approach, 2nd ed. Oxford: IRL Press.
- Klvana, M., Pavlova, M., Koudelakova, T., Chaloupkova, R., Dvorak, P., Prokop, Z., Stsiapanava, A., Kuty, M., Kuta-Smatanova, I., Dohnalek, J., Kulhanek, P., Wade, R. C. & Damborsky, J. (2009). J. Mol. Biol. 392, 1339–1356. [DOI] [PubMed]
- Kulakova, A. N., Larkin, M. J. & Kulakov, L. A. (1997). Microbiology, 143, 109–115. [DOI] [PubMed]
- Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
- Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Acta Cryst. D53, 240–255. [DOI] [PubMed]
- Newman, J., Peat, T. S., Richard, R., Kan, L., Swanson, P. E., Affholter, J. A., Holmes, I. H., Schindler, J. F., Unkefer, C. J. & Terwilliger, T. C. (1999). Biochemistry, 38, 16105–16114. [DOI] [PubMed]
- Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
- Pavlova, M., Klvana, M., Prokop, Z., Chaloupkova, R., Banas, P., Otyepka, M., Wade, R. C., Tsuda, M., Nagata, Y. & Damborsky, J. (2009). Nature Chem. Biol. 5, 727–733. [DOI] [PubMed]
- Schindler, J. F., Naranjo, P. A., Honaberger, D. A., Chang, C.-H., Brainard, J. R., Vanderberg, L. A. & Unkefer, C. J. (1999). Biochemistry, 38, 5772–5778. [DOI] [PubMed]
- Stsiapanava, A., Dohnalek, J., Gavira, J. A., Kuty, M., Koudelakova, T., Damborsky, J. & Kuta Smatanova, I. (2010). Acta Cryst. D66, 962–969. [DOI] [PubMed]
- Teng, T.-Y. (1990). J. Appl. Cryst. 23, 387–391.
- Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25. [DOI] [PubMed]


